STOCKHOLM – Elekta (EKTA-B.ST) today announced new research on MR‑guided adaptive radiotherapy across multiple cancer indications, presented at the 2026 European Society for Radiotherapy and Oncology (ESTRO) annual congress.
","regulatory":false},{"id":2994,"name":"Invitation to the presentation of Elekta’s fiscal year 2025/26","url":"https://ir.elekta.com/investors/press-releases/2026/invitation-to-the-presentation-of-elektas-fiscal-year-202526/","date":"2026-05-13T05:30:00.000Z","intro":"STOCKHOLM – Elekta (EKTA-B.ST) invites analysts and investors to a presentation of the fiscal year 2025/26 at 9:00 a.m. CEST on May 28. The year-end report will be published at 7:30 a.m. CEST on the same day.
","regulatory":false},{"id":2983,"name":"Invitation to Elekta's Capital Markets Day on June 17, 2026","url":"https://ir.elekta.com/investors/press-releases/2026/invitation-to-elektas-capital-markets-day-on-june-17-2026/","date":"2026-04-17T05:00:00.000Z","intro":"STOCKHOLM – Elekta (EKTA-B.ST) is pleased to invite investors, analysts, and other interested stakeholders to attend its Capital Markets Day on June 17, 2026, at 14:00 CEST. The event will include presentations from Jakob Just-Bomholt, Elekta’s CEO; Klara Eiritz, CFO, as well as other members of Elekta’s leadership team.
","regulatory":false},{"id":2972,"name":"Third quarter, November–January 2025/26","url":"https://ir.elekta.com/investors/press-releases/2026/third-quarter-novemberjanuary-202526/","date":"2026-03-05T06:30:00.000Z","intro":"Third quarter
","regulatory":true},{"id":2970,"name":"Change in Elekta’s Nomination Committee for the Annual General Meeting 2026","url":"https://ir.elekta.com/investors/press-releases/2026/change-in-elektas-nomination-committee-for-the-annual-general-meeting-2026/","date":"2026-02-25T06:30:00.000Z","intro":"STOCKHOLM – Elekta (EKTA-B.ST) announces a change to the company’s Nomination Committee for the Annual General Meeting 2026 to be held on September 3, 2026.
","regulatory":true}]